Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.40 |
| ▸ | VNN1 | O95497 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845845 | 0.89 | VNN1 (0.35) | VNN1 | |
| SCHEMBL19454417 | 0.86 | OPRK1 (0.42) | OPRK1ALDH1A1 | |
| SCHEMBL19704362 | 0.82 | OPRK1 (0.39) | OPRK1ALDH1A1 | |
| SCHEMBL17675350 | 0.78 | OPRK1 (0.62) | OPRK1 | |
| SCHEMBL17856546 | 0.78 | OPRK1 (0.46) | OPRK1 | |
| SCHEMBL17845839 | 0.77 | OPRK1 (0.48) | OPRK1VNN1 | |
| SCHEMBL17845846 | 0.76 | OPRK1 (0.46) | OPRK1 | |
| SCHEMBL17675584 | 0.76 | OPRK1 (0.51) | OPRK1 | |
| SCHEMBL19454416 | 0.73 | VNN1 (0.33) | OPRK1VNN1 | |
| SCHEMBL20619501 | 0.71 | NR4A2 (0.41) | OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626126-B2 | Compounds | PULMOCIDE LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-20190092791-A1 | COMPOUNDS | PULMOCIDE LIMITED (GB) | 2019-03-28 | — | — | US | disclosed |
| US-10160772-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2018-12-25 | — | — | US | disclosed |
| EP-3233867-B1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | PULMOCIDE LTD (GB) | 2018-10-17 | — | — | EP | disclosed |
| US-20170355718-A1 | Novel 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355718-A1 | Novel 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| EP-3233867-A1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | Pulmocide Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017175000-A1 | COMPOUNDS | PULMOCIDE LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2016097761-A1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | PULMOCIDE LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626126-B2 | Compounds | QDPR, TXNRD2, TXNRD3 | OPRK1 4316/4885VNN1 427/4885ALDH1A1 932/4885 |
| US-20190092791-A1 | COMPOUNDS | QDPR, TXNRD2, TXNRD3 | OPRK1 4316/4885VNN1 427/4885ALDH1A1 932/4885 |
| US-10160772-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | ZC3HAV1, DDX5, DPP4 | OPRK1 3339/4885VNN1 1072/4885ALDH1A1 1709/4885 |
| US-20170355718-A1 | Novel 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | DDX5, ZC3HAV1, MAVS | OPRK1 3678/4885VNN1 794/4885ALDH1A1 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.